Home » Industry News »
ESMO 2020 Oncology electronic prescribing record study of UK first-line (1L) NSCLC patients
Retrospective Analysis of Real-World Treatment Patterns and Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Starting First-Line Systemic Therapy in the United Kingdom…
Real-world evidence (RWE) generates largest study population in patients with aNSCLC
Patients EPRs were utilised to generate RWE on treatment patterns and clinical outcomes for patients with aNSCLC in the UK 1003 patients who started a…
Institute for Clinical and Economic Review (ICER) to use real-world evidence (RWE) from Aetion in assessments
ICER has long sought data generated outside clinical trials to enhance our understanding of how medical treatments perform in the real world Only 15% of…
Yescarta real-world evidence (RWE) study enrolment two years ahead of schedule
Yescarta is the first CAR-T therapy approved by the FDA in the treatment of large B-cell lymphoma The Center for International Blood and Marrow Transplant…
Real-world evidence (RWE) solutions market expected to be worth over $5 billion by 2027
Previous forecasts stated that the RWE market was set to grow to being worth over $1 billion by 2023. However, now research shows the market…
FDA see expanded role for real-world evidence (RWE); Merck KGaA and Pfizer generate RWE for regulatory submission
RWE has the potential to both accelerate approval timelines and reduce the costs of drug development RWE studies must uphold established standards of evidence –…
Big data and AI: the UN reported, for the first time, half of humanity is now connected to the Internet
Big data that are routinely generated from, for example, electronic medical records and smart devices have become progressively easier and cheaper to collect, process, and…
Real-world evidence supports CAR-T-cell therapy’s safety and efficacy
A retrospective study in 275 (treated) patients with relapsed or refractory large B-cell lymphoma found (Yescarta) axicabtagene ciloleucel gave similar responses to those seen in…
Synapse and FDA collaborate to swiftly generate real-world data (RWD) in COVID-19 patients with cancer
The collaboration is already yielding useful results and aims to tackle the following: Investigating methods to derive RWD from multiple sources including electronic health records, registries and…
NICE and Flatiron partner to utilise real-world oncology data in informing decisions about cancer therapy access
Flatiron Health are already partnered with the FDA in the US since 2016, with whom they have explored real-world outcomes and alternative study methods Experts…